Current guidelines for prostate cancer (PCa) consider life expectancy (LE) an important factor when making screening and treatment decisions. For patients with LE<10 years, most guidelines recommend against PCa screening and active surveillance or definitive treatment of low risk disease. (1,2) Nevertheless, recent work has demonstrated that men with limited LE often undergo PSA screening and biopsy for PCa.(3,4) With an increasing emphasis on guideline-directed management, pragmatic tools for point-of-care 10-year LE estimates are needed to inform these clinical decisions. This article is protected by copyright. All rights reserved.
BJU international. 2017 Feb 15 [Epub ahead of print]
Scott R Hawken, Gregory B Auffenberg, David C Miller, Brian R Lane, Michael L Cher, Firas Abdollah, Hyunsoon Cho, Khurshid R Ghani, Michigan Urological Surgery Improvement Collaborative
Department of Urology, University of Michigan, Ann Arbor, MI, USA., College of Human Medicine, Michigan State University, Section of Urology, Spectrum Health Medical Group, Grand Rapids, MI, USA., Department of Urology, Wayne State University, Detroit, MI, USA., VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA., Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea.